Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308394524> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4308394524 abstract "<h3>Background</h3> Anti-PD-1 therapy improves recurrence-free survival in patients with resectable Stage III/IV melanoma. Immune-related adverse events (irAEs) represent a challenge for patient care especially in the setting of adjuvant management and may serve as a predictor for therapeutic benefit. We sought to evaluate the incidence of immune related adverse events (irAEs) in melanoma patients receiving adjuvant anti-PD-1 therapy and assess the impact of corticosteroid and non-corticosteroid-based therapy on recurrence-free and overall survival at the University of Pittsburgh Medical Center (UPMC) cohort. <h3>Methods</h3> This retrospective, single-center study reviewed adult patients undergoing treatment for Stage III melanoma between 1996 and 2021 who received either pembrolizumab or nivolumab. Patients were further excluded if they did not receive adjuvant treatment with anti-PD-1 therapy, had prior exposure to immunotherapy or BRAF inhibitors, or did not have sufficient follow-up to allow necessary data collection. The resulting 231 patients were stratified into two cohorts – those treated with >10mg prednisone equivalent for longer than two weeks during anti-PD-1 therapy, and those who were not. <h3>Results</h3> Of 231 patients reviewed, 123 (53%) developed an irAE of any grade; 57 patients required systemic steroids during adjuvant therapy, with 11 (5%) patients that received steroids and another immunosuppressing agent. Use of steroids did not reduce OS (HR = 1.037, 95% CI 0.4517, 2.381; p=0.93) or RFS (HR = 1.026, 95% CI 0.6198, 1.699; p=0.92). Development of irAEs was associated with improved OS (HR = 0.3698, 95% CI 0.1682, 0.8127; p=0.010), and melanoma specific survival (HR 0.3608, 95% CI: 0.145, 0.8974; p=0.022), but not RFS (HR = 0.8908, 95% CI 0.5659, 1.402; p=0.62). In a multivariable analysis adjusting for age, sex, and stage development of irAEs remained significantly associated with increased overall survival (HR = 0.4079, 95% CT 0.1826, 0.9112; p=0.0288). <h3>Conclusions</h3> IrAEs are common in patients treated with adjuvant anti-PD-1 and frequently require treatment with systemic corticosteroids. The development of irAEs during adjuvant therapy is associated with improved OS, but not RFS. Exposure to systemic steroids during adjuvant therapy did not have an impact on OS or RFS. These results provide reassurance that the use of systemic steroids during adjuvant treatment of fully-resected stage III melanoma does not have a negative impact on disease recurrence or survival. <h3>Ethics Approval</h3> Approved by the University of Pittsburgh Institutional Review Board under Study ID: STUDY21080074." @default.
- W4308394524 created "2022-11-11" @default.
- W4308394524 creator A5007239425 @default.
- W4308394524 creator A5023333652 @default.
- W4308394524 creator A5033020983 @default.
- W4308394524 creator A5042720711 @default.
- W4308394524 creator A5047119138 @default.
- W4308394524 creator A5056417464 @default.
- W4308394524 creator A5087880055 @default.
- W4308394524 creator A5089221394 @default.
- W4308394524 date "2022-11-01" @default.
- W4308394524 modified "2023-09-25" @default.
- W4308394524 title "1267 The effect of immunosuppression during anti-PD-1 treatment for stage III melanoma" @default.
- W4308394524 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1267" @default.
- W4308394524 hasPublicationYear "2022" @default.
- W4308394524 type Work @default.
- W4308394524 citedByCount "0" @default.
- W4308394524 crossrefType "proceedings-article" @default.
- W4308394524 hasAuthorship W4308394524A5007239425 @default.
- W4308394524 hasAuthorship W4308394524A5023333652 @default.
- W4308394524 hasAuthorship W4308394524A5033020983 @default.
- W4308394524 hasAuthorship W4308394524A5042720711 @default.
- W4308394524 hasAuthorship W4308394524A5047119138 @default.
- W4308394524 hasAuthorship W4308394524A5056417464 @default.
- W4308394524 hasAuthorship W4308394524A5087880055 @default.
- W4308394524 hasAuthorship W4308394524A5089221394 @default.
- W4308394524 hasBestOaLocation W43083945241 @default.
- W4308394524 hasConcept C120665830 @default.
- W4308394524 hasConcept C121332964 @default.
- W4308394524 hasConcept C121608353 @default.
- W4308394524 hasConcept C126322002 @default.
- W4308394524 hasConcept C143998085 @default.
- W4308394524 hasConcept C146357865 @default.
- W4308394524 hasConcept C151730666 @default.
- W4308394524 hasConcept C167135981 @default.
- W4308394524 hasConcept C197934379 @default.
- W4308394524 hasConcept C2777658100 @default.
- W4308394524 hasConcept C2777701055 @default.
- W4308394524 hasConcept C2777863537 @default.
- W4308394524 hasConcept C2777982462 @default.
- W4308394524 hasConcept C2778720950 @default.
- W4308394524 hasConcept C2780030458 @default.
- W4308394524 hasConcept C2780057760 @default.
- W4308394524 hasConcept C2780252810 @default.
- W4308394524 hasConcept C502942594 @default.
- W4308394524 hasConcept C61511704 @default.
- W4308394524 hasConcept C71924100 @default.
- W4308394524 hasConcept C86803240 @default.
- W4308394524 hasConceptScore W4308394524C120665830 @default.
- W4308394524 hasConceptScore W4308394524C121332964 @default.
- W4308394524 hasConceptScore W4308394524C121608353 @default.
- W4308394524 hasConceptScore W4308394524C126322002 @default.
- W4308394524 hasConceptScore W4308394524C143998085 @default.
- W4308394524 hasConceptScore W4308394524C146357865 @default.
- W4308394524 hasConceptScore W4308394524C151730666 @default.
- W4308394524 hasConceptScore W4308394524C167135981 @default.
- W4308394524 hasConceptScore W4308394524C197934379 @default.
- W4308394524 hasConceptScore W4308394524C2777658100 @default.
- W4308394524 hasConceptScore W4308394524C2777701055 @default.
- W4308394524 hasConceptScore W4308394524C2777863537 @default.
- W4308394524 hasConceptScore W4308394524C2777982462 @default.
- W4308394524 hasConceptScore W4308394524C2778720950 @default.
- W4308394524 hasConceptScore W4308394524C2780030458 @default.
- W4308394524 hasConceptScore W4308394524C2780057760 @default.
- W4308394524 hasConceptScore W4308394524C2780252810 @default.
- W4308394524 hasConceptScore W4308394524C502942594 @default.
- W4308394524 hasConceptScore W4308394524C61511704 @default.
- W4308394524 hasConceptScore W4308394524C71924100 @default.
- W4308394524 hasConceptScore W4308394524C86803240 @default.
- W4308394524 hasLocation W43083945241 @default.
- W4308394524 hasOpenAccess W4308394524 @default.
- W4308394524 hasPrimaryLocation W43083945241 @default.
- W4308394524 hasRelatedWork W2903811712 @default.
- W4308394524 hasRelatedWork W2981883049 @default.
- W4308394524 hasRelatedWork W3029766637 @default.
- W4308394524 hasRelatedWork W3128878661 @default.
- W4308394524 hasRelatedWork W3157008565 @default.
- W4308394524 hasRelatedWork W3200550458 @default.
- W4308394524 hasRelatedWork W3215044659 @default.
- W4308394524 hasRelatedWork W4281630205 @default.
- W4308394524 hasRelatedWork W4292373623 @default.
- W4308394524 hasRelatedWork W4308181630 @default.
- W4308394524 isParatext "false" @default.
- W4308394524 isRetracted "false" @default.
- W4308394524 workType "article" @default.